Amring expands generic product launches
Amring Pharmaceuticals has announced that in addition to launching generic oncology drug, arsenic trioxide injection, in November 2018, the company expects to launch four additional generic drugs in 2019.
These five drugs are distributed to the retail, hospital, and institutional channels.
“We are pleased with our progress during the past year and look forward to realizing the benefits of our product launches and future business development activities in 2019. Amring intends to start marketing and distributing these other four products in the United States this year,” Daniel Carbery, Amring president and CEO said.
These five drugs are distributed to the retail, hospital, and institutional channels.
“We are pleased with our progress during the past year and look forward to realizing the benefits of our product launches and future business development activities in 2019. Amring intends to start marketing and distributing these other four products in the United States this year,” Daniel Carbery, Amring president and CEO said.